|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MMP2 |
Gene summary for MMP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MMP2 | Gene ID | 4313 |
| Gene name | matrix metallopeptidase 2 | |
| Gene Alias | CLG4 | |
| Cytomap | 16q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P08253 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4313 | MMP2 | AEH-subject1 | Human | Endometrium | AEH | 5.07e-19 | -6.37e-01 | -0.3059 |
| 4313 | MMP2 | AEH-subject2 | Human | Endometrium | AEH | 1.85e-24 | -7.09e-01 | -0.2525 |
| 4313 | MMP2 | AEH-subject3 | Human | Endometrium | AEH | 9.84e-33 | -7.89e-01 | -0.2576 |
| 4313 | MMP2 | AEH-subject4 | Human | Endometrium | AEH | 2.50e-13 | -6.27e-01 | -0.2657 |
| 4313 | MMP2 | AEH-subject5 | Human | Endometrium | AEH | 2.36e-40 | -8.18e-01 | -0.2953 |
| 4313 | MMP2 | EEC-subject1 | Human | Endometrium | EEC | 1.99e-26 | -7.44e-01 | -0.2682 |
| 4313 | MMP2 | EEC-subject2 | Human | Endometrium | EEC | 1.20e-41 | -8.14e-01 | -0.2607 |
| 4313 | MMP2 | EEC-subject3 | Human | Endometrium | EEC | 3.14e-31 | -6.47e-01 | -0.2525 |
| 4313 | MMP2 | EEC-subject4 | Human | Endometrium | EEC | 7.49e-29 | -7.61e-01 | -0.2571 |
| 4313 | MMP2 | EEC-subject5 | Human | Endometrium | EEC | 6.74e-33 | -7.70e-01 | -0.249 |
| 4313 | MMP2 | GSM5276935 | Human | Endometrium | EEC | 3.89e-30 | -7.50e-01 | -0.123 |
| 4313 | MMP2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.79e-24 | -7.22e-01 | -0.1869 |
| 4313 | MMP2 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.49e-24 | -6.90e-01 | -0.1875 |
| 4313 | MMP2 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.99e-28 | -6.57e-01 | -0.1883 |
| 4313 | MMP2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.71e-39 | -7.78e-01 | -0.1934 |
| 4313 | MMP2 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.19e-42 | -8.16e-01 | -0.1917 |
| 4313 | MMP2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 6.57e-48 | -8.29e-01 | -0.1916 |
| 4313 | MMP2 | P2T-E | Human | Esophagus | ESCC | 1.02e-09 | 3.20e-01 | 0.1177 |
| 4313 | MMP2 | P4T-E | Human | Esophagus | ESCC | 1.56e-04 | 1.39e+00 | 0.1323 |
| 4313 | MMP2 | P9T-E | Human | Esophagus | ESCC | 1.22e-07 | 1.70e+00 | 0.1131 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000646521 | Thyroid | ATC | signal peptide processing | 11/6293 | 14/18723 | 7.46e-04 | 4.14e-03 | 11 |
| GO:007123022 | Thyroid | ATC | cellular response to amino acid stimulus | 37/6293 | 71/18723 | 9.80e-04 | 5.21e-03 | 37 |
| GO:003300214 | Thyroid | ATC | muscle cell proliferation | 107/6293 | 248/18723 | 1.03e-03 | 5.47e-03 | 107 |
| GO:000840613 | Thyroid | ATC | gonad development | 96/6293 | 221/18723 | 1.40e-03 | 7.25e-03 | 96 |
| GO:00487715 | Thyroid | ATC | tissue remodeling | 78/6293 | 175/18723 | 1.60e-03 | 8.04e-03 | 78 |
| GO:00349821 | Thyroid | ATC | mitochondrial protein processing | 10/6293 | 13/18723 | 1.77e-03 | 8.71e-03 | 10 |
| GO:004865916 | Thyroid | ATC | smooth muscle cell proliferation | 81/6293 | 184/18723 | 2.02e-03 | 9.60e-03 | 81 |
| GO:00451374 | Thyroid | ATC | development of primary sexual characteristics | 97/6293 | 227/18723 | 2.47e-03 | 1.14e-02 | 97 |
| GO:004866016 | Thyroid | ATC | regulation of smooth muscle cell proliferation | 78/6293 | 180/18723 | 4.00e-03 | 1.73e-02 | 78 |
| GO:000756517 | Thyroid | ATC | female pregnancy | 82/6293 | 193/18723 | 6.04e-03 | 2.42e-02 | 82 |
| GO:00466603 | Thyroid | ATC | female sex differentiation | 51/6293 | 114/18723 | 8.62e-03 | 3.28e-02 | 51 |
| GO:00085853 | Thyroid | ATC | female gonad development | 43/6293 | 95/18723 | 1.19e-02 | 4.22e-02 | 43 |
| GO:00613831 | Thyroid | ATC | trabecula morphogenesis | 22/6293 | 43/18723 | 1.30e-02 | 4.55e-02 | 22 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0541525 | Endometrium | AEH | Diabetic cardiomyopathy | 86/1197 | 203/8465 | 2.62e-23 | 1.22e-21 | 8.90e-22 | 86 |
| hsa0541826 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
| hsa0467026 | Endometrium | AEH | Leukocyte transendothelial migration | 37/1197 | 114/8465 | 4.51e-07 | 6.11e-06 | 4.47e-06 | 37 |
| hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
| hsa049337 | Endometrium | AEH | AGE-RAGE signaling pathway in diabetic complications | 28/1197 | 100/8465 | 2.11e-04 | 1.80e-03 | 1.32e-03 | 28 |
| hsa0491525 | Endometrium | AEH | Estrogen signaling pathway | 35/1197 | 138/8465 | 3.10e-04 | 2.40e-03 | 1.75e-03 | 35 |
| hsa05415111 | Endometrium | AEH | Diabetic cardiomyopathy | 86/1197 | 203/8465 | 2.62e-23 | 1.22e-21 | 8.90e-22 | 86 |
| hsa05418112 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
| hsa04670111 | Endometrium | AEH | Leukocyte transendothelial migration | 37/1197 | 114/8465 | 4.51e-07 | 6.11e-06 | 4.47e-06 | 37 |
| hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
| hsa0493314 | Endometrium | AEH | AGE-RAGE signaling pathway in diabetic complications | 28/1197 | 100/8465 | 2.11e-04 | 1.80e-03 | 1.32e-03 | 28 |
| hsa04915111 | Endometrium | AEH | Estrogen signaling pathway | 35/1197 | 138/8465 | 3.10e-04 | 2.40e-03 | 1.75e-03 | 35 |
| hsa0541526 | Endometrium | EEC | Diabetic cardiomyopathy | 86/1237 | 203/8465 | 2.59e-22 | 9.46e-21 | 7.05e-21 | 86 |
| hsa0541827 | Endometrium | EEC | Fluid shear stress and atherosclerosis | 45/1237 | 139/8465 | 7.76e-08 | 1.22e-06 | 9.07e-07 | 45 |
| hsa0467027 | Endometrium | EEC | Leukocyte transendothelial migration | 36/1237 | 114/8465 | 2.97e-06 | 3.91e-05 | 2.91e-05 | 36 |
| hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
| hsa0493321 | Endometrium | EEC | AGE-RAGE signaling pathway in diabetic complications | 28/1237 | 100/8465 | 3.68e-04 | 3.03e-03 | 2.26e-03 | 28 |
| hsa0491526 | Endometrium | EEC | Estrogen signaling pathway | 34/1237 | 138/8465 | 1.19e-03 | 8.02e-03 | 5.98e-03 | 34 |
| hsa0541535 | Endometrium | EEC | Diabetic cardiomyopathy | 86/1237 | 203/8465 | 2.59e-22 | 9.46e-21 | 7.05e-21 | 86 |
| hsa0541836 | Endometrium | EEC | Fluid shear stress and atherosclerosis | 45/1237 | 139/8465 | 7.76e-08 | 1.22e-06 | 9.07e-07 | 45 |
| Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MMP2 | SNV | Missense_Mutation | c.1116N>C | p.Lys372Asn | p.K372N | P08253 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MMP2 | SNV | Missense_Mutation | rs759302357 | c.682G>A | p.Ala228Thr | p.A228T | P08253 | protein_coding | deleterious(0) | probably_damaging(0.935) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
| MMP2 | SNV | Missense_Mutation | novel | c.1512N>T | p.Met504Ile | p.M504I | P08253 | protein_coding | tolerated(0.2) | benign(0) | TCGA-EW-A6S9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MMP2 | SNV | Missense_Mutation | c.970G>A | p.Asp324Asn | p.D324N | P08253 | protein_coding | deleterious(0.01) | benign(0.074) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MMP2 | SNV | Missense_Mutation | rs772094112 | c.275N>G | p.Asn92Ser | p.N92S | P08253 | protein_coding | tolerated(0.73) | benign(0) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| MMP2 | SNV | Missense_Mutation | c.1295G>C | p.Arg432Pro | p.R432P | P08253 | protein_coding | tolerated(0.35) | probably_damaging(0.999) | TCGA-EK-A2PI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MMP2 | SNV | Missense_Mutation | c.1116N>C | p.Lys372Asn | p.K372N | P08253 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MMP2 | SNV | Missense_Mutation | c.1345C>G | p.Pro449Ala | p.P449A | P08253 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MMP2 | SNV | Missense_Mutation | c.1818C>G | p.Ile606Met | p.I606M | P08253 | protein_coding | tolerated(0.14) | probably_damaging(0.999) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MMP2 | SNV | Missense_Mutation | c.1896C>G | p.Phe632Leu | p.F632L | P08253 | protein_coding | tolerated(0.24) | probably_damaging(0.966) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 178101832 | ||
| 4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | SERMS | 15576828 | ||
| 4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | MARIMASTAT | MARIMASTAT | ||
| 4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | PMID29130358-Compound-SB-3CT | |||
| 4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | BMS-275291 | REBIMASTAT | 15041713 | |
| 4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | SIMVASTATIN | SIMVASTATIN | 16436088 | |
| 4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | POLYPHENOL | 15324350 | ||
| 4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | HEPARAN SULFATE | 12972284 | ||
| 4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | PRAVASTATIN | PRAVASTATIN | 15842807 | |
| 4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | RO-26-2853 |
| Page: 1 2 3 4 5 6 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |